LumiraDx Investor Presentation Deck

3 Respiratory Coagulation Disease Area and Test Diabetes Global Health Inflammation lumiraDx™ COVID Ultra CRP Flu A/B Ultra RSV Ultra Strep A INR Cardiovascular BNP D-Dimer NT-ProBNP 2022 2023 Pipeline Plan HS Troponin Na/K Lipids HbAlc TB HIV Viral Load CRP Focacifonin Concept Qual Immunoassay Feasibility Development Quant Immunoassay Verification & Validation Copyright © 2022 LumiraDx Ltd. All Rights Reserved. Worldwide Molecular Regulatory E Enzyme Planned Submissions IVDR/ CE Mark Complete Complete Complete Complete Complete H1 2073 H2 2022 H2 2022 H2 2023 Complete Complete H1 2023 Note: Regulatory timelines refer to submission dates and launch dates will be subject to review by corresponding regulatory authorities. Expected FDA 510K H1 223 H1 2023 H1123 HT 2023 H2 2022 H1 2023 HI 2023 H1 2023 HV 2023 Hi 2023 H2 2023 H2 2022 TBC TBC H2 2023 WHO PQ H2 2023 H2 2022 H2 2023 H2 2023 H2 2023 H2 2023 H2 2022 Metabolic/Electrochemical 35

View entire presentation